Piper Sandler on Orchestra BioMed Inc. (OBIO): 'Recent Updates a Clear Positive for the Story'
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $15.00 price target on Orchestra BioMed Inc. (NASDAQ: OBIO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
